- Biotech Snap
- Posts
- WHO adds ArkBio ́s RSV drug to its priority list
WHO adds ArkBio ́s RSV drug to its priority list
The World Health Organization added ArkBio’s antiviral drug Ziresovir to its PADO RSV Drug Development Priority List, recognizing it as a promising treatment for respiratory syncytial virus in children.
Why it matters: RSV is a major global cause of infant hospitalization. WHO’s prioritization via PADO could fast-track development and global adoption of effective pediatric RSV therapies, especially in low-resource regions.
Backstory: Ziresovir, developed by Shanghai-based ArkBio, is an orally administered RSV fusion (F protein) inhibitor. It binds to the pre-F protein conformation of the virus and prevents viral entry into human cells and has shown promising safety and efficacy results in early trials across Asia.
Big picture: RSV kills approximately 100,000 children under 5 and causes 3.6 million hospitalizations per year. With limited RSV treatments for young children, WHO’s backing positions Ziresovir to fill a critical therapeutic gap and support global pediatric health equity.
What is PADO?: PADO stands for Paediatric Drug Optimization. It is a WHO's legally binding international priority (based on WHA69.20 resolution) that accelerates the development of high-demand pediatric drugs by building consensus among regulators, funders, and manufacturers.